文献速递肿瘤 PET/CT

68Ga-RGD2 PET显像揭示非小细胞肺癌与小细胞肺癌患者αvβ3的组间异质性与组内异质性

Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-12

本研究纳入31例病理确诊肺癌患者(21例NSCLC、10例SCLC),以68Ga-RGD2 PET/CT定量比较αvβ3表达,并以18F-FDG PET/CT为参照。SCLC患者68Ga-RGD2摄取处于本底水平且显著低于NSCLC患者,免疫组化示NSCLC病灶αvβ3阳性而SCLC阴性,两类肺癌均存在明显瘤内异质性。

要点

  • SCLC患者68Ga-RGD2摄取处于本底水平且显著低于NSCLC患者。
  • NSCLC与SCLC患者18F-FDG SUVmax和SUVmean无显著差异。
  • 免疫组化示NSCLC病灶αvβ3阳性、SCLC样本阴性。

核心结论

  • SCLC患者68Ga-RGD2摄取显著低于NSCLC患者,提示SCLC中cilengitide的αvβ3靶点水平较低。
  • NSCLC与SCLC均存在明显的瘤内αvβ3异质性。
  • 这种组间与组内异质性可能改进当前αvβ3靶向治疗与诊断显像在肺癌中的应用。

研究设计与样本

  • 研究纳入31例病理确诊肺癌患者,其中21例为非小细胞肺癌(NSCLC)、10例为小细胞肺癌(SCLC)。
  • 采用68Ga-RGD2 PET/CT显像,并于次日采集18F-FDG PET/CT作为参照。
  • 定量比较标准摄取值(SUV)与肿瘤/非靶(T/NT)比值,并用免疫组化分析NSCLC与SCLC病灶中血管生成标志物αvβ3的表达。

主要发现

  • NSCLC与SCLC患者的18F-FDG SUVmax和SUVmean无显著差异。
  • SCLC患者68Ga-RGD2摄取的SUV与T/NT测量均处于本底水平,且显著低于NSCLC患者。
  • 68Ga-RGD2 SUVmean的极差在NSCLC组为4.5、在SCLC组为2.2;变异系数在NSCLC原发灶为36.2%、在SCLC原发灶为39.3%。
  • 部分NSCLC病例中观察到原发灶与推测远处转移灶之间的异质性。
  • 免疫染色显示αvβ3整合素表达于NSCLC病灶的细胞与新生血管,而SCLC样本表达为阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Integrin αvβ3 is the therapeutic target of the anti-angiogenic drug cilengitide. The objective of this study was to compare αvβ3 levels in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients, by using the positron emission tomography (PET) tracer 68Ga-labeled dimerized-RGD (68Ga-RGD2). METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using 68Ga-RGD2.18F-FDG PET/CT images were also acquired on the consecutive day as reference. The standard uptake values (SUV) and the tumor/nontarget (T/NT) values were quantitatively compared. Expression of the angiogenesis marker αvβ3 in NSCLC and SCLC lesions was analyzed by immunohistochemistry. RESULTS: The 18F-FDG SUVmax and the SUVmean were not significantly different between NSCLC and SCLC patients. The 68Ga-RGD2 uptake of SCLC patients was at background levels in both SUV and T/NT measurements and was significantly lower than that of NSCLC patients. The range value of 68Ga-RGD2 SUVmean was 4.5 in the NSCLC group and 2.2 in the SCLC group, while the variation coefficient was 36.2% and 39.3% in NSCLC and SCLC primary lesions, respectively. Heterogeneity between primary lesions and putative distant metastases was also observed in some NSCLC cases. Immunostaining showed that αvβ3 integrin was expressed in the cells and neovasculature of NSCLC lesions, while SCLC samples had negative expression. CONCLUSIONS: The uptake of 68Ga-RGD2 in SCLC patients is significantly lower than that in NSCLC patients, indicating a lower αvβ3 target level for cilengitide in SCLC. Apparent intra-tumor heterogeneities of αvβ3 also exist in both NSCLC and SCLC. Such inter- and intra-heterogeneity of αvβ3 may potentially improve current applications of αvβ3-targeted therapy and diagnostic imaging in lung cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kang F, Wang Z, Li G, et al. Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging. Eur J Nucl Med Mol Imaging. 2017. PMID: 28405726. doi:10.1007/s00259-017-3696-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。